Role of lymphopenia and inflammation in COVID-19 pathogenesis

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: Irini  Sereti
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2024
Award: $162,051
Funding agency: National Institute of Allergy and Infectious Diseases

In order to evaluate the pathogenesis of COVID with a focus on lymphopenia, inflammation and coagulopathy, we have opened a protocol to obtain clinical samples (peripheral blood mononuclear cells, serum and plasma, nasal swabs) from people with active COVID-19 disease. In addition, recovered patients may enroll and have a similar sample collection for comparison purposes. 
In addition, we are interested in how immunocompromised patients may be responding to COVID-19 vaccines by assessing people T-cell and antibody responses.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Acute><Affect><Antibody Response><Biological Markers><Blood Coagulation Disorders><Blood Plasma><Blood Serum><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 infected patient><COVID-19 pathogenesis><COVID-19 patient><COVID-19 positive patient><COVID-19 vaccine><COVID-19 virus><COVID19 pathogenesis><COVID19 patient><COVID19 positive patient><COVID19 virus><CV-19><Clinical><Clotting><CoV emergence><CoV-2><CoV2><Coagulation><Coagulation Disorder><Coagulation Process><Coagulopathy><Complement Activation><Coronavirus Infectious Disease 2019><Disease><Disorder><Dysfunction><Endothelium><Enrollment><Evaluation><Functional disorder><Immunity><Immunochemical Immunologic><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic><Immunological><Immunologically><Immunologics><Immunosuppressed Host><Inflammasome><Inflammation><Inflammatory><Intervention><Intervention Strategies><Lymphocytopenia><Lymphopenia><PBMC><Pathogenesis><Pathway interactions><Patients><Peripheral Blood Mononuclear Cell><Persons><Phenotype><Physiopathology><Plasma><Plasma Serum><Protocol><Protocols documentation><Reticuloendothelial System, Serum, Plasma><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 infected patient><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 vaccine><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Syndrome><T-Cells><T-Lymphocyte><Vaccination><Variant><Variation><Wuhan coronavirus><bio-markers><biologic marker><biomarker><bleeding disorder><clotting disorder><complement pathway regulation><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 infected patient><coronavirus disease 2019 pathogenesis><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 pathogenesis><coronavirus disease-19 patient><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><coronavirus patient><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><enroll><hCoV19><immunosuppressed patient><insight><interest><interventional strategy><mortality><nCoV><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><nasal swab><new CoV><new corona virus><new coronavirus><novel CoV><novel corona virus><novel coronavirus><pandemic><pandemic disease><pathophysiology><pathway><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><respiratory><sample collection><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><social role><specimen collection><thymus derived lymphocyte><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID>